gastrointestinal stromal tumor

gastrointestinal stromal tumor
Name	Gastrointestinal stromal tumor
Field	Oncology, Gastroenterology, Pathology
Symptoms	Abdominal pain, gastrointestinal bleeding, palpable mass
Complications	Metastasis to liver, peritoneal dissemination, intestinal obstruction
Onset	Adulthood
Causes	Mutations in KIT, PDGFRA
Risks	Age, familial syndromes
Diagnosis	Endoscopy, computed tomography, immunohistochemistry
Treatment	Surgical resection, tyrosine kinase inhibitors
Prognosis	Variable; dependent on size, mitotic index, mutation status

gastrointestinal stromal tumor

Gastrointestinal stromal tumor is a mesenchymal neoplasm of the alimentary canal that most often arises in the stomach and small intestine. It is principally characterized by activating mutations affecting receptor tyrosine kinases and a clinical spectrum ranging from indolent nodules to aggressive metastatic disease. Management requires coordinated care drawing on surgical, medical oncology, and diagnostic pathology expertise.

Overview

Gastrointestinal stromal tumors are the commonest mesenchymal tumors of the digestive tract and were distinguished as a distinct entity in the late twentieth century through immunohistochemical and molecular discoveries. They predominantly affect middle-aged and older adults and may present sporadically or as part of familial cancer predisposition syndromes. Key institutions and investigators in the field include academic centers and consortia that advanced molecular characterization and targeted therapy development.

Signs and symptoms

Presentation varies from incidental, asymptomatic lesions to acute abdomen. Common complaints include abdominal pain, overt or occult gastrointestinal bleeding, anemia, and palpable mass; less commonly, obstruction or perforation occurs. Symptom recognition often occurs during evaluation by specialists at hospitals, referral centers, or through imaging ordered by gastroenterologists or emergency departments.

Pathophysiology and genetics

Most tumors harbor activating mutations in the receptor tyrosine kinase genes KIT or PDGFRA leading to constitutive signaling through downstream pathways that promote proliferation and survival. Secondary resistance mutations may emerge during treatment, involving ATP-binding pocket or activation loop residues. A minority of cases lack KIT/PDGFRA alterations and are associated with succinate dehydrogenase complex deficiencies, neurofibromatosis type 1, or BRAF and NTRK fusions. Molecular findings guide targeted therapy choice and are central to precision oncology workflows developed at major cancer centers.

Diagnosis

Diagnosis integrates endoscopic assessment, cross-sectional imaging, and tissue-based testing. Upper or lower endoscopy with biopsy, computed tomography and magnetic resonance imaging are used for localization and staging, while endoscopic ultrasound can assist in sampling. Histopathology with immunohistochemical profiling—most notably KIT (CD117) and DOG1 staining—confirms lineage, and molecular testing identifies actionable mutations. Multidisciplinary tumor boards at academic hospitals often determine sequencing of surgery and systemic therapy; expert pathology review at reference laboratories refines risk stratification.

Treatment

Localized tumors are managed primarily by complete surgical resection with negative margins, employing open or minimally invasive techniques as appropriate. Adjuvant therapy with imatinib, a small-molecule tyrosine kinase inhibitor, reduces recurrence risk in high-risk patients selected by tumor size, mitotic count, and mutation status. For advanced, unresectable, or metastatic disease, systemic therapy sequencing includes imatinib, sunitinib, regorafenib, and later-line agents developed through translational research collaborations. Emerging approaches include mutation-directed agents, combination regimens, and investigational strategies evaluated in clinical trials at research hospitals and cooperative groups.

Prognosis and outcomes

Prognosis depends on tumor size, mitotic activity, anatomical site, and molecular genotype; gastric tumors generally have a more favorable outcome than small intestinal lesions. Risk stratification systems estimate recurrence risk and inform follow-up intensity, with long-term surveillance using periodic imaging and clinical assessment. While many patients achieve durable disease control with targeted agents, acquired resistance and metastatic progression remain critical challenges addressed by ongoing research in molecular oncology and drug development.

Category:Neoplasms